Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A11 | P48066 | 4/20 | 0.46 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.46 |
| ▸ | KIF11 | P52732 | 7/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | TK2 | O00142 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.41 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13575115 | 1.00 | SLC6A11 (0.46) | SLC6A11SLC6A1KIF11KCNH2TK2 | |
| SCHEMBL6040158 | 1.00 | SLC6A11 (0.46) | SLC6A11SLC6A1KIF11KCNH2TK2 | |
| SCHEMBL2385290 | 1.00 | SLC6A11 (0.46) | SLC6A11SLC6A1KIF11KCNH2TK2 | |
| SCHEMBL6570212 | 0.92 | SLC6A11 (0.47) | SLC6A11SLC6A1KIF11KCNH2TK2 | |
| SCHEMBL992028 | 0.91 | SLC6A11 (0.50) | SLC6A11SLC6A1KIF11KCNH2MEN1 | |
| SCHEMBL2490410 | 0.91 | SLC6A11 (0.50) | SLC6A11SLC6A1KIF11KCNH2MEN1 | |
| SCHEMBL2288433 | 0.90 | SLC6A11 (0.43) | SLC6A11SLC6A1KIF11KCNH2TK2 | |
| SCHEMBL24207815 | 0.87 | KIF11 (0.55) | SLC6A1KIF11TK2MEN1CYP1A2 | |
| SCHEMBL3485522 | 0.87 | KIF11 (0.55) | SLC6A1KIF11TK2MEN1CYP1A2 | |
| SCHEMBL24207971 | 0.87 | KIF11 (0.55) | SLC6A1KIF11TK2MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250302995-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | SHIVALILA CHIKDU SHAKTI (US) | 2025-10-02 | — | — | US | disclosed |
| EP-4522744-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | Wave Life Sciences Ltd. (SG) | 2025-03-19 | — | — | EP | disclosed |
| WO-2023220440-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-11-16 | — | — | WO | disclosed |
| US-20230312630-A1 | PHOSPHORAMIDITE SYNTHESIS ON-DEMAND | AARHUS UNIVERSITET (DK) | 2023-10-05 | — | — | US | disclosed |
| CN-109072221-A | The design method of variation primer | 大研医器株式会社 | 2018-12-21 | — | — | CN | disclosed |
| US-8026349-B2 | Polynucleotide synthesis labeling chemistry | DHARMACON, INC. (US) | 2011-09-27 | — | — | US | disclosed |
| US-20080009612-A1 | Novel Polynucleotide Synthesis Labeling Chemistry | DHARMACON, INC. | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009612-A1 | Novel Polynucleotide Synthesis Labeling Chemistry | POLN, POLRMT, POLM | SLC6A11 3189/4885SLC6A1 3259/4885KIF11 1922/4885 |
| US-20230312630-A1 | PHOSPHORAMIDITE SYNTHESIS ON-DEMAND | RNGTT, PPA1, PNP | SLC6A11 3617/4885SLC6A1 4239/4885KIF11 4046/4885 |
| US-20250302995-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | ADAR, NSUN2, RNGTT | SLC6A11 4777/4885SLC6A1 4770/4885KIF11 3613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.